Clinicopathological characteristics and survival of spinal cord astrocytomas.
Adolescent
Adult
Astrocytoma
/ genetics
Biomarkers, Tumor
/ genetics
Chemotherapy, Adjuvant
Child
Child, Preschool
Female
Histones
/ genetics
Humans
Male
Middle Aged
Mutation
Neoplasm Grading
Neurosurgical Procedures
/ adverse effects
Radiotherapy, Adjuvant
Retrospective Studies
Spinal Cord Neoplasms
/ genetics
Time Factors
Treatment Outcome
Young Adult
H3 K27M
astrocytoma
clinicopathological feature
spinal cord tumor
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
17
03
2020
revised:
13
06
2020
accepted:
14
07
2020
pubmed:
11
8
2020
medline:
21
7
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
Due to their rarity, the clinicopathological characteristics and prognostic factors of spinal cord gliomas are still unclear. Here, we aimed to clarify these issues in a cohort of 108 spinal cord astrocytomas. We characterized the clinicopathological characteristics, including 2016 World Health Organization (WHO) grade, age, sex, location, segment length, resection, pre- and postsurgery, Modified McCormick Scale (MMS), radio- and chemotherapy, and Ki-67 and H3 K27M mutations, in 108 spinal cord astrocytomas through heatmaps. The Cox regression analysis and Kaplan-Meier curves were used to study the prognostic value of these clinicopathological features. There are a total 38 H3 K27M-mutant tumors, including 31 cases with histological grade II/III tumors. The age of low-grade astrocytoma patients (WHO grade I/II, n = 54) was significantly younger (27.0 vs 35.5 years, P = .001) than those with high-grade tumors (WHO grade III/IV, n = 54). All patients underwent surgical resection with neurophysiological monitoring, and the surgery did not result in significant changes in MMS. The presurgery MMS was associated with overall survival in the high-grade subgroup (P = .008) but not in the low-grade subgroup (P = .312). While, the high content of resection improved the survival of only patients with low-grade astrocytomas (P = .016) but not those with high-grade astrocytomas (P = .475). Both the low-grade and high-grade astrocytomas had no obvious benefit from neither adjuvant chemotherapy nor radiotherapy (all P > .05). We characterized the clinicopathological characteristics and their prognostic values in 108 spinal cord astrocytomas, which could help with evidence-based management of spinal cord astrocytomas.
Sections du résumé
BACKGROUND
Due to their rarity, the clinicopathological characteristics and prognostic factors of spinal cord gliomas are still unclear. Here, we aimed to clarify these issues in a cohort of 108 spinal cord astrocytomas.
METHODS
We characterized the clinicopathological characteristics, including 2016 World Health Organization (WHO) grade, age, sex, location, segment length, resection, pre- and postsurgery, Modified McCormick Scale (MMS), radio- and chemotherapy, and Ki-67 and H3 K27M mutations, in 108 spinal cord astrocytomas through heatmaps. The Cox regression analysis and Kaplan-Meier curves were used to study the prognostic value of these clinicopathological features.
RESULTS
There are a total 38 H3 K27M-mutant tumors, including 31 cases with histological grade II/III tumors. The age of low-grade astrocytoma patients (WHO grade I/II, n = 54) was significantly younger (27.0 vs 35.5 years, P = .001) than those with high-grade tumors (WHO grade III/IV, n = 54). All patients underwent surgical resection with neurophysiological monitoring, and the surgery did not result in significant changes in MMS. The presurgery MMS was associated with overall survival in the high-grade subgroup (P = .008) but not in the low-grade subgroup (P = .312). While, the high content of resection improved the survival of only patients with low-grade astrocytomas (P = .016) but not those with high-grade astrocytomas (P = .475). Both the low-grade and high-grade astrocytomas had no obvious benefit from neither adjuvant chemotherapy nor radiotherapy (all P > .05).
CONCLUSIONS
We characterized the clinicopathological characteristics and their prognostic values in 108 spinal cord astrocytomas, which could help with evidence-based management of spinal cord astrocytomas.
Identifiants
pubmed: 32777166
doi: 10.1002/cam4.3364
pmc: PMC7541164
doi:
Substances chimiques
Biomarkers, Tumor
0
Histones
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6996-7006Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Spine (Phila Pa 1976). 2012 May 20;37(12):E727-35
pubmed: 22609727
Neurosurgery. 2019 May 1;84(5):1072-1081
pubmed: 29718432
Curr Neuropharmacol. 2017;15(1):88-97
pubmed: 27157264
Medicine (Baltimore). 2017 Mar;96(13):e6500
pubmed: 28353599
Neuro Oncol. 2018 Jan 10;20(1):123-131
pubmed: 29016894
Cell. 2018 Nov 29;175(6):1665-1678.e18
pubmed: 30343896
Cancer Lett. 2016 Jun 1;375(2):263-273
pubmed: 26966000
J Neurooncol. 2001 Mar;52(1):85-94
pubmed: 11451207
J Clin Neurosci. 2019 Mar;61:14-21
pubmed: 30528541
Front Oncol. 2012 Dec 28;2:205
pubmed: 23293772
JCI Insight. 2019 Aug 13;5:
pubmed: 31408440
Brain Pathol. 2016 Sep;26(5):569-80
pubmed: 26517431
Neuro Oncol. 2017 Aug 1;19(8):1127-1134
pubmed: 28201752
J Neurooncol. 2018 Sep;139(3):609-616
pubmed: 29796723
Neuro Oncol. 2017 Aug 1;19(8):1025-1034
pubmed: 28371920
Cancer Med. 2020 Oct;9(19):6996-7006
pubmed: 32777166
Neuro Oncol. 2018 May 18;20(6):729-742
pubmed: 29216380
J Neurooncol. 2012 Sep;109(2):385-9
pubmed: 22678696
Acta Neuropathol. 2019 Apr;137(4):637-655
pubmed: 30770999
Carcinogenesis. 2019 Oct 16;40(10):1229-1239
pubmed: 31157866
J Neurooncol. 2013 Jun;113(2):259-66
pubmed: 23483435
Neuro Oncol. 2013 Apr;15(4):406-12
pubmed: 23322747
Acta Neuropathol Commun. 2020 Mar 30;8(1):40
pubmed: 32228694
Spine (Phila Pa 1976). 2018 May 15;43(10):E565-E573
pubmed: 29135884
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1307-11
pubmed: 23433793
Eur Spine J. 2016 Dec;25(12):4067-4079
pubmed: 26984877
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1451-6
pubmed: 20346593
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Acta Neuropathol. 2019 Feb;137(2):297-306
pubmed: 30460397
Spine (Phila Pa 1976). 2014 Apr 1;39(7):533-40
pubmed: 24384651
Neurosurgery. 2008 Jul;63(1):55-60; discussion 60-1
pubmed: 18728568
Acta Neuropathol. 2014 Oct;128(4):573-81
pubmed: 25047029
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
J Spine Surg. 2019 Mar;5(1):19-30
pubmed: 31032435
Asian Spine J. 2015 Dec;9(6):935-41
pubmed: 26713128
J Neurooncol. 2000 May;47(3):219-24
pubmed: 11016738
Eur Spine J. 2009 Oct;18(10):1397-422
pubmed: 19562388
J Neurol. 2012 Apr;259(4):768-70
pubmed: 21964752
Mod Pathol. 2019 Jan;32(1):4-15
pubmed: 30291347
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931